Please check your internet connection and try again.
# Diadzein + Genistein + Palmitoylethanolamide
## Overview
This combination product contains daidzein and genistein, which are isoflavones found in soy, and palmitoylethanolamide (PEA), a fatty acid amide. These ingredients are often marketed for various health benefits, including pain relief and anti-inflammatory effects.
## Primary Indications
This combination is primarily marketed for its potential anti-inflammatory and analgesic properties. It is often used for conditions such as:
* Neuropathic pain
* Osteoarthritis pain
* Pelvic pain
* Endometriosis-related pain
## Adult Dosing
Dosing varies widely depending on the specific product and intended use. Common dosages found in available formulations include:
* **Daidzein:** 50-200 mg daily
* **Genistein:** 50-200 mg daily
* **Palmitoylethanolamide (PEA):** 300-1200 mg daily, often divided into multiple doses.
Specific product labeling and physician guidance are essential for determining the appropriate dose.
## Pediatric Dosing
There is insufficient data to establish pediatric dosing for this combination product.
## Dose Adjustments
No specific dose adjustments are established for renal or hepatic impairment. Caution should be exercised in patients with pre-existing conditions.
## Contraindications
* Hypersensitivity to any component of the product.
* Pregnancy and breastfeeding (due to lack of safety data and potential hormonal effects of isoflavones).
## Adverse Effects
Adverse effects are generally mild and may include gastrointestinal upset (nausea, diarrhea, abdominal pain). Some individuals may experience allergic reactions.
## Key Drug Interactions
* **Hormone-sensitive conditions:** Isoflavones like daidzein and genistein may possess weak estrogenic activity, potentially interacting with hormone-sensitive conditions or therapies.
* **Anticoagulants/Antiplatelets:** Theoretical concern for increased bleeding risk due to antiplatelet effects of isoflavones, though not well-established clinically.
* **CYP450 substrates:** Isoflavones may inhibit or induce certain CYP450 enzymes, potentially altering the metabolism of other drugs. Clinical significance is often unclear.
## Monitoring
* Monitor for symptom improvement and any adverse effects.
* Consider monitoring for potential hormonal effects in susceptible individuals.
## Clinical Pearls
* The efficacy and safety of this combination product are not definitively established by large-scale clinical trials for many of its purported uses.
* PEA is an endogenous substance, and its supplementation is generally considered to have a good safety profile.
* Isoflavones are found in soy products; dietary intake should be considered when evaluating supplementation.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult with a qualified healthcare provider to determine the appropriateness of any medication or treatment for a specific patient condition. Ensure you have reviewed the most current prescribing information, including contraindications, warnings, and adverse reactions, before administering any medication.*
